NASDAQ: KYNBKyntra Bio Inc Stock Ownership - Who owns Kyntra Bio?
Insider buying vs selling
Have Kyntra Bio Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| David Delucia | Chief Financial Officer | 2026-06-06 | 52 | $6.71 | $348.92Sell |
| Thane Wettig | CEO | 2026-06-06 | 198 | $6.71 | $1.33kSell |
| Thane Wettig | CEO | 2026-05-14 | 2,800 | $7.09 | $19.85kBuy |
| Thane Wettig | CEO | 2026-05-14 | 2,800 | $7.09 | $19.85kBuy |
| Thane Wettig | CEO | 2026-05-14 | 2,800 | $7.09 | $19.85kBuy |
| Thane Wettig | CEO | 2026-03-06 | 277 | $6.84 | $1.89kSell |
| David Delucia | Chief Financial Officer | 2026-03-06 | 60 | $6.84 | $410.40Sell |
| Thane Wettig | CEO | 2025-12-06 | 259 | $8.42 | $2.18kSell |
| David Delucia | Chief Financial Officer | 2025-12-06 | 52 | $8.42 | $437.84Sell |
| Thane Wettig | CEO | 2025-11-17 | 2,700 | $9.10 | $24.57kBuy |
KYNB insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when KYNB insiders and whales buy or sell their stock.
KYNB Shareholders
What type of owners hold Kyntra Bio Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Astellas Pharma Inc | 122.70% | 4,968,367 | $39.50M | Insider |
| Thomas B. Neff | 65.36% | 2,646,636 | $21.04M | Insider |
| Rory B. Riggs | 24.73% | 1,001,463 | $7.96M | Insider |
| Miguel Madero | 10.50% | 425,246 | $3.38M | Insider |
| Enrique A. Conterno | 9.94% | 402,522 | $3.20M | Insider |
| Christine Chung | 7.28% | 294,903 | $2.34M | Insider |
| Pat Cotroneo | 6.78% | 274,536 | $2.18M | Insider |
| Thomas F. Kearns Jr. | 6.17% | 249,764 | $1.99M | Insider |
| K. Peony Yu | 4.75% | 192,292 | $1.53M | Insider |
| Julian N. Stern | 4.28% | 173,244 | $1.38M | Insider |
KYNB vs Biotech Stocks
Kyntra Bio Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.